Celltrion Healthcare Co.,Ltd.
Matt Eddleston has extensive work experience in the healthcare industry. Matt is currently the Commercial & Operations Director at Celltrion Healthcare Co.,Ltd. since January 2022, where they previously served as the Commercial Director from September 2019 to March 2022. Prior to joining Celltrion Healthcare, Matt worked as the Vice Chair of the British Biosimilars Association (BBA) starting from February 2019. Before that, they were the Biosimilars Business Unit Lead at Fresenius Kabi from May 2018 to September 2019. Matt also held various roles at Pfizer, including Regional Commercial Director, Biosimilars from July 2017 to May 2018, and Director, Global Health & Value, Biosimilars from January 2016 to June 2017. Matt began their career at Hospira as the Head of Market Access, Biosimilars from August 2014 to December 2015.
Matt Eddleston's education history begins in 1994 when they attended the Lincoln International Business School at the University of Lincoln. Matt completed their Bachelor of Arts in International Business in 1998 at the Hull Campus of the university.
There is no specific information given about when Matt attended the Auckland University of Technology, but they obtained a Bachelor of Business in Business Administration and Management from this institution at some point.
Matt also attended the Brunel Business School for a postgraduate short course in Health Economics.
In the future, in 2023, Matt plans to pursue a Foundation MBA at The University of Salford, in the field of Business Administration.
In addition to their formal education, Matt has obtained a certification from The Association of the British Pharmaceutical Industry (ABPI), although the specific details of this certification, including the obtained month and year, are not provided.
This person is not in any offices
Celltrion Healthcare Co.,Ltd.
Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines through an extensive global network that spans more than 110 different countries. Celltrion Healthcare provides REMSIMA, the world's first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of autoimmune disease, and innovative biopharmaceutical medications to help increase patient access to advanced therapies around the world. For additional information on our guidelines, please visit: https://bit.ly/3QyOyt7